Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Similar articles for PubMed (Select 22870036)

1.

Proof of concept in cardiovascular risk: the paradoxical findings in blood pressure and lipid abnormalities.

Fuchs FD, Fuchs SC, Moreira LB, Gus M.

Vasc Health Risk Manag. 2012;8:437-42. doi: 10.2147/VHRM.S32585. Epub 2012 Jul 12. Review.

2.

Assessing the impact of medication use on trends in major coronary risk factors in older British men: a cohort study.

Hardoon SL, Whincup PH, Wannamethee SG, Lennon LT, Capewell S, Morris RW.

Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):502-8. doi: 10.1097/HJR.0b013e3283378865.

5.

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Oct 11;11:125. doi: 10.1186/1475-2840-11-125. Review.

6.

Assessment of cardiovascular risk factors after renal transplantation: a step towards reducing graft failure.

Kumar R, Brar J, Yacoub R, Khan T, Zachariah M, Venuto R.

Transplant Proc. 2012 Jun;44(5):1270-4. doi: 10.1016/j.transproceed.2012.01.111.

PMID:
22663999
7.

Lipid control in patients with diabetes mellitus.

Betteridge DJ.

Nat Rev Cardiol. 2011 May;8(5):278-90. doi: 10.1038/nrcardio.2011.23. Epub 2011 Mar 15. Review.

PMID:
21403658
8.

Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies.

Rückert IM, Schunk M, Holle R, Schipf S, Völzke H, Kluttig A, Greiser KH, Berger K, Müller G, Ellert U, Neuhauser H, Rathmann W, Tamayo T, Moebus S, Andrich S, Meisinger C.

Cardiovasc Diabetol. 2012 May 8;11:50.

9.

Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).

Erdine S, Ro YM, Tse HF, Howes LG, Aguilar-Salinas CA, Chaves H, Guindy R, Chopra P, Moller RA, Schou IM; Gemini-AALA Investigators.

J Hum Hypertens. 2009 Mar;23(3):196-210. doi: 10.1038/jhh.2008.114. Epub 2008 Sep 18.

PMID:
18800143
10.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

11.

Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program.

Abraham I, MacDonald K, Hermans C, Aerts A, Lee C, Brié H, Vancayzeele S.

Vasc Health Risk Manag. 2011;7:209-35. doi: 10.2147/VHRM.S9434. Epub 2011 Mar 31. Review.

12.

ESH-ESC guidelines for the management of hypertension.

Erdine S, Ari O, Zanchetti A, Cifkova R, Fagard R, Kjeldsen S, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, Staessen J, van Zwieten P, Waeber B, Williams B.

Herz. 2006 Jun;31(4):331-8.

PMID:
16810473
13.

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Nov 14;11:140. doi: 10.1186/1475-2840-11-140. Review.

14.

Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.

Shinkai H.

Vasc Health Risk Manag. 2012;8:323-31. doi: 10.2147/VHRM.S25238. Epub 2012 May 15. Review.

15.

Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.

Miyares MA, Davis K.

Vasc Health Risk Manag. 2012;8:483-93. doi: 10.2147/VHRM.S29010. Epub 2012 Aug 23. Review.

16.
17.

Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention.

Millán J, Pintó X, Muñoz A, Zúñiga M, Rubiés-Prat J, Pallardo LF, Masana L, Mangas A, Hernández-Mijares A, González-Santos P, Ascaso JF, Pedro-Botet J.

Vasc Health Risk Manag. 2009;5:757-65. Epub 2009 Sep 18. Review.

18.

Lipid effects of antihypertensive medications.

Deano R, Sorrentino M.

Curr Atheroscler Rep. 2012 Feb;14(1):70-7. doi: 10.1007/s11883-011-0214-z. Review.

PMID:
22037772
19.
20.

Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.

Jialal I, Smith G.

Metab Syndr Relat Disord. 2012 Jun;10(3):159-60. doi: 10.1089/met.2012.1500. Epub 2012 May 8. No abstract available.

PMID:
22568574
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk